Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699 Shaw, 2013, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, 368, 2385, 10.1056/NEJMoa1214886 Shaw, 2014, Ceritinib in ALK-rearranged non-small-cell lung cancer, N Engl J Med, 370, 1189, 10.1056/NEJMoa1311107 Jänne, 2015, AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer, N Engl J Med, 372, 1689, 10.1056/NEJMoa1411817 Sequist, 2015, Rociletinib in EGFR-mutated non-small-cell lung cancer, N Engl J Med, 372, 1700, 10.1056/NEJMoa1413654 Camidge, 2014, Acquired resistance to TKIs in solid tumours: learning from lung cancer, Nat Rev Clin Oncol, 11, 473, 10.1038/nrclinonc.2014.104 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643 Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, 372, 2018, 10.1056/NEJMoa1501824 Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011 Spira, 2015, Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR) [abstract], J Clin Oncol, 33, 8010, 10.1200/jco.2015.33.15_suppl.8010 Francisco, 2010, The PD-1 pathway in tolerance and autoimmunity, Immunol Rev, 236, 219, 10.1111/j.1600-065X.2010.00923.x Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239 Dong, 2002, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat Med, 8, 793, 10.1038/nm730 Iwai, 2002, Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade, Proc Natl Acad Sci USA, 99, 12293, 10.1073/pnas.192461099 Greenwald, 2005, The B7 family revisited, Annu Rev Immunol, 23, 515, 10.1146/annurev.immunol.23.021704.115611 Freeman, 2000, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J Exp Med, 192, 1027, 10.1084/jem.192.7.1027 Garon, 2015, Pembrolizumab 2 mg/kg Q3W for previously treated, PD-L1-positive advanced NSCLC [abstract], J Thorac Oncol, 10, 3024 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Wolchok, 2009, Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin Cancer Res, 15, 7412, 10.1158/1078-0432.CCR-09-1624 Efron, 1977, The efficiency of Cox's likelihood function for censored data, J Am Stat Assoc, 72, 557, 10.1080/01621459.1977.10480613 Miettinen, 1985, Comparative analysis of two rates, Stat Med, 4, 213, 10.1002/sim.4780040211 Garon, 2014, Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial, Lancet, 384, 665, 10.1016/S0140-6736(14)60845-X Brahmer, 2014, Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC [abstract], J Clin Oncol, 32, 8021, 10.1200/jco.2014.32.15_suppl.8021 Papadimitrakopoulou, 2015, Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohorts A and C [abstract], J Clin Oncol, 33, 8031, 10.1200/jco.2015.33.15_suppl.8031 Patnaik, 2015, Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D [abstract], J Clin Oncol, 33, 8011, 10.1200/jco.2015.33.15_suppl.8011 Gettinger, 2014, B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction, Cancer J, 20, 281, 10.1097/PPO.0000000000000063 McLaughlin, 2015, Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer, JAMA Oncol Dong, 1999, B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion, Nat Med, 12, 1365, 10.1038/70932 Schalper, 2014, In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas, Clin Cancer Res, 20, 2773, 10.1158/1078-0432.CCR-13-2702 Rizvi, 2015, Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348 Ascierto, 2013, The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment, J Transl Med, 11, 54, 10.1186/1479-5876-11-54 Messina, 2012, 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?, Sci Rep, 2, 765, 10.1038/srep00765